ClinicalTrials.gg
CompletedNCT00174278Updated Aug 5, 2008

Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

A Phase 3 interventional study of Somatropin in Growth Hormone Deficiency and Growth Retardation, sponsored by Pfizer. Completed at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2008-08-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
53rd of 60
14 · median 66
Started
1997
with 1 other
Phase 3
23 of 60
2 open now
Registered
7th of 60
by date
Lead sponsor
5 of 60
Pfizer

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 53rd largest by enrollment, is one of 2 that started in 1997, is one of 23 in phase 3, and was the 7th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To assess the effect of long-term treatment by Genotonorm on linear growth

03

Conditions studied

  • Growth Hormone Deficiency
  • Growth Retardation

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014
  • All patients who have stopped during one year will be included if a signed written

Exclusion criteria

Exclusion Criteria:

  • Endocrine disease, except well substituted hypothyroidism
  • Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The main efficacy variable is the height SDS (SEMPE) before and after treatment.

  2. The standing height of the patients is measured during the inclusion visit and at each follow-up visit.

  3. The height measurements are always performed at the same time of the day by

  4. use of a wallmounted device (e.g. Harpenden Stadiometer).

  5. Each child has to be measured three times, the mean of these measurements is recorded in the Case Report Form as the present height.

  6. The body weight is measured by use of a balance scale.

  7. Puberty stage is assessed (according to Tanner´s cotation) at the same visits as height is measured.

07

Study locations

1 site
  • Pfizer Investigational Site
    Paris, France
08

References and documents

Publications

  • David H, Aupiais C, Louveau B, Quartier P, Jacqz-Aigrain E, Carel JC, Simon D. Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4578-4587. doi: 10.1210/jc.2017-01455. PubMed 29029101 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 1997 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Feb 1997
CompletionActual
Oct 2006
Last update
Aug 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00174278
Lead sponsor
Pfizer
First posted
Sep 15, 2005
Start date
Feb 1997
Completion
Oct 2006
Last update
Aug 5, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion